Press Releases

Date Title and Summary Additional Formats
Toggle Summary Aravive Achieves Second Development Milestone from 3D Medicines
Milestone is Based on Approval of 3D Medicines’ IND in China to Participate in Aravive’s AVB-500 (3D-299) Phase 3 Clinical Trial for Platinum Resistant Ovarian Cancer HOUSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing innovative
View HTML
Toggle Summary Aravive Added to the Russell 2000® and Russell 3000® Indexes
HOUSTON , June 30, 2020 (GLOBE NEWSWIRE) -- Aravive , Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis, today announced that the Company has been added to the Russell
View HTML
Toggle Summary Aravive and 3D Medicines Announce Strategic Collaboration to Develop and Commercialize AVB-500 in Greater China
Aravive to Receive $12 Million Signing Payment , u p to an Additional $20 7   M illion in Future Milestone Payments plus Tiered Royalties 3D Medicines to Lead Clinical Development and Commercialization of AVB-500 in Greater China HOUSTON and SHANGHAI, China , Nov.
View HTML
Toggle Summary Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Investigator-sponsored study being conducted in clinical collaboration with Aravive and AstraZeneca HOUSTON and WILMINGTON, Del. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of
View HTML
Toggle Summary Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform
HOUSTON and SHANGHAI , April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced a strategic collaboration
View HTML
Toggle Summary Aravive Announces $21.0 Million Registered Direct Offering with Eshelman Ventures, LLC Priced At-The-Market
HOUSTON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities purchase agreement with Eshelman Ventures, LLC to sell 2,875,000 shares of common stock at a price
View HTML
Toggle Summary Aravive Announces AVB-500 Improves Anti-Tumor Effects when Combined with Anti-Angiogenic Bevacizumab or PARP Inhibitor Olaparib in Preclinical Models of Uterine Cancer
Inhibition of GAS6/AXL signaling induces ‘BRCAness’ in preclinical model of ovarian cancer, increasing response to platinum chemotherapy and PARP inhibitor Multiple Abstracts Published on Website of the Society for Gynecologic Oncology 2020 Annual Meeting Recorded Webcast and Posters to be
View HTML
Toggle Summary Aravive Announces Board Composition and Executive Management Transitions
Healthcare Entrepreneur Fred Eshelman , Pharm.D., Appointed Board Chairman Aravive’s Chief Scientific Officer, Gail McIntyre , Ph.D., Appointed CEO Aravive to Host Conference Call Today at 9:00 AM  ET HOUSTON , April 09, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
View HTML
Toggle Summary Aravive Announces Board Member Transition to Advisory Role
HOUSTON, Dec. 31, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that Dr. Ray Tabibiazar will be stepping down from the Aravive Board of Directors but will remain an advisor to the company, effective
View HTML
Toggle Summary Aravive Announces Dose Escalation of AVB-500 in Recurrent Platinum Resistant Ovarian Cancer Phase 1b Trial
Dose escalation of AVB-500 to 20mg/kg dose follows positive recommendation by independent Data Monitoring Committee review Plan to initiate Phase 2/3 study in Platinum Resistant Ovarian Cancer by year end 2020 HOUSTON , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc.
View HTML